The purpose of this study is to see if providing effective antimalarial treatment at home for parents/guardians to treat their children for malaria will lead to an improved health outcome compared to conventional healthcare.

Condition	Intervention	Phase
Malaria Anemia	Behavior: Provision of antimalarial treatment at home	Phase IV

Further Study Details: 

Primary Outcomes: The primary outcome measurement will be treatment incidence density (antimalarial treatments received per time at risk) for each study arm.
Secondary Outcomes: Mean days of fever per participant; Incidence of febrile episodes; Mean haemoglobin at study end; Change in mean haemoglobin between the start and end of the intervention; Incidence of visits to health care facilities (drug shops, clinics, pharmacies, hospitals) and hospitalizations per participant; Mortality rate; Economic outcomes
Expected Total Enrollment:  540

Population: Representative sample of Ugandan children aged 1 to 5 years from 400 households (approximately 540 children).

Clinical Site: The study will be conducted in the Mulago III parish community of Kampala, Uganda.

Study Duration: 13 months

Study Intervention: *Pilot period: After enrollment, households will participate in a one month pilot period to test the household pictorial diaries. At the end of the pilot period, households will be randomized to participation in the home-based management of fever (HBMF) arm or standard care arm for the remainder of the study (12 months). *HBMF arm: Households randomized to the HBMF group will be provided with pre-packaged coartemether to keep at home. Primary caregivers will be instructed to treat children participating in the study empirically with coartemether at home when the child develops fever. Study personnel will distribute drugs and educate the caregivers about administration of drugs, recognition of danger signs of fever/malaria, and when to seek additional care. *Standard care: Households randomized to the standard care arm will be asked to continue their current behaviour and to manage fever in their children as they would normally.

Measurements: Household diaries and monthly visits. Primary caregivers will be asked to keep a diary regarding the health of study participants for the duration of the study (13 months). Information on illnesses, treatments given, visits to health care facilities, and health care expenditures will be collected. Study personnel will visit the households monthly to collect completed diaries. At each visit, questionnaires will be administered to gather additional data on the health of the participants and treatment seeking behaviour.

Clinical and laboratory evaluations: Temperature, height, weight, mid-upper arm circumference, spleen size, haemoglobin, and thick blood smear will be assessed at enrollment, and at the beginning and end of the intervention period.

Study Objectives: 1. To measure the impact of home-based management of fever with coartemether on malaria-related morbidity compared to the current standard of care in the community. 2. To measure the impact of home-based management of fever with coartemether on economic measures compared to the current standard of care in the community.

Primary outcome: Treatment incidence density (treatments per time at risk) for each treatment arm

Secondary clinical outcomes: 1) mean days of fever; 2) incidence of febrile episodes; 3) mean haemoglobin at study end; 4) change in mean haemoglobin; 5) prevalence of splenomegaly; 6) prevalence of parasitaemia; 7) incidence of visits to health care facilities, and hospitalizations; 8) mortality rate; 9) anthropometric measurements; 10) proportion of "appropriate" treatments; 11) proportion of delayed treatments; 12) treatment incidence density of treatments given at >50% and at full dose

Economic outcomes: 1) household cost/febrile episode; 2) household costs for treatment of febrile episode/month; 3) provider cost/child for delivery of HBMF; 4) estimated provider facility cost/patient for uncomplicated fever, and for severe disease; 5) total net cost/child/year; 6) net cost/additional child appropriately treated; 7) net cost/day of fever averted

Ages Eligible for Study:  1 Year   -   5 Years,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

• Age 1 - 5 years
• Agreement of parents or guardians to provide informed consent
• Live in Mulago III Parish

Exclusion Criteria:

• History of any known serious chronic disease requiring frequent medical care (e.g. AIDS, sickle cell disease, malignancy)
• Intention to move from Kampala during the 13 month follow-up period
• History of serious side effects to study medications
• Weight < 10 kg
• Severe malnutrition defined as a weight-for-height or height-for-age Z-score < – 3

Please refer to this study by ClinicalTrials.gov identifier  NCT00115921

Sarah G Staedke, MD      256-41-530692    staedke@itsa.ucsf.edu
Christopher JM Whitty, FRCP      44-20-7299-4715    christopher.whitty@lshtm.ac.uk

Uganda
      MU - UCSF Malaria Research Collaboration, PO Box 7475, Kampala,  Uganda

Study chairs or principal investigators

Sarah G Staedke, MD,  Principal Investigator,  University of California, San Francisco   
Christopher JM Whitty, FRCP,  Principal Investigator,  London School of Hygiene & Tropical Medicine   

Study ID Numbers:  ITCRVG40
Record last reviewed:  June 2005
Last Updated:  June 30, 2005
Record first received:  June 26, 2005
ClinicalTrials.gov Identifier:  NCT00115921
Health Authority: Uganda: National Council for Science and Technology
ClinicalTrials.gov processed this record on 2005-07-05